How the FDA helped this drugmaker overcome its manufacturing dilemma

A recent decision by the Food and Drug Administration will allow Keryx Biopharmaceuticals to overcome a large obstacle in the manufacturing of its kidney drug Auryxia, according to the Boston Business Journal.

In August, the Boston-based drugmaker stopped manufacturing Auryxia due to issues with its manufacturer over converting active pharmaceutical ingredients into finished pills.

On Wednesday, the FDA approved the use of a second manufacturer, allowing Keryx to reinitiate manufacturing processes and supply the drug to wholesalers.

"Getting a second drug product manufacturer approved was an important step to ensuring long-term supply of Auryxia is consistently available to patients," said Keryx CEO Greg Madison in a statement.

More articles on supply chain:

FDA may allow medical companies to promote drugs, devices for off-label uses
J.B. Hunt to add hundreds of trucks next year despite industry slowdown: 3 takeaways
Global supply chain risk index on the rise: 4 things to know

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Top 40 Articles from the Past 6 Months